View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

WINFARM : Modalités de mise à disposition du Rapport Financier Semestr...

WINFARM : Modalités de mise à disposition du Rapport Financier Semestriel 2025. COMMUNIQUE DE PRESSE Loudéac, le 28 octobre 2025 MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025 WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, annonce que son rapport financier semestriel 2025 a été déposé auprès de l’Autorité des Marchés Financiers (AMF), le 28 octobre 2025. Ce document est disponible sur le site de la Société à l’adresse -group.com et sur le site de l’AMF (-france.org). Il est également tenu à disp...

 PRESS RELEASE

Pharming Group announces presentations at 2025 ACAAI Annual Scientific...

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10. Five posters will present positive new clinical, economic, and comparative data for RUCONEST® (recombinant C1 esterase inhibi...

 PRESS RELEASE

Pharming Group provides update on previously announced G&A expense red...

Pharming Group provides update on previously announced G&A expense reduction plan Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&A) expenses to optimize capital allocation across the organization.  The restructuring includes a redesign of Pharming’s organizational structure and a 20% net reduction in non-com...

 PRESS RELEASE

Very sharp increase in EBITDA, cash generation and debt reduction in H...

Very sharp increase in EBITDA, cash generation and debt reduction in H1 2025 PRESS RELEASE Loudéac, 2 October 2025 Very sharp increase in EBITDA, cash generation and debt reduction in H1 2025 Outlook for 2025: continued growth, improvement in operating profitability and debt reduction WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in distance-selling of products and solutions for the agricultural and livestock industry, is today publishing its consolidated results for the first half of 2025. At its meeting on 1 October 2025, the Board of Directors approv...

 PRESS RELEASE

Très forte hausse de l’EBITDA, génération de cash et baisse de l’endet...

Très forte hausse de l’EBITDA, génération de cash et baisse de l’endettement au 1er semestre 2025 COMMUNIQUE DE PRESSE Loudéac, 2 octobre 2025 Très forte hausse de l’EBITDA, génération de cash et baisse de l’endettement au 1er semestre 2025 Perspectives 2025 : poursuite de la croissance, amélioration de la rentabilité opérationnelle et désendettement WINFARM (code ISIN : FR0014000P11 - mnémonique : ALWF), n°1 français de la vente à distance pour le monde agricole, publie aujourd’hui ses résultats consolidés du 1er semestre 2025. Le Conseil d’administration du 1er octobre 2025 a...

 PRESS RELEASE

Pharming Group announces U.S. FDA acceptance and Priority Review of su...

Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on positive data from multinational Phase III study in children aged 4 to 11 years with APDSPDUFA target action date of January 31, 2026 Leiden, the Netherlands, October 1, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: ...

Christophe Chaput
  • Christophe Chaput
 PRESS RELEASE

Pharming Group promoted to the Euronext AMX® index

Pharming Group promoted to the Euronext AMX® index Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025. Euronext Amsterdam announced the results of its review of the AMX index, which comprises 25 companies based on free-float market capitalization and liquidity. This marks Pharming’s return to the AMX index, reflecting the Company’s strong growth momentum. Fabrice Chouraqui, Ch...

 PRESS RELEASE

Revenue growth of 6.4% in H1 2025

Revenue growth of 6.4% in H1 2025 PRESS RELEASE Loudéac, 3 September 2025 Revenue growth of 6.4% in H1 2025 Growth in all of the Group’s activities Improvement in EBITDA expected over full-year 2025 WINFARM (ISIN: FR0014000P11 - ticker: ALWF), the leading French player in consulting, services and distance-selling of products and solutions for the agricultural and livestock industry, is today publishing its revenue figures for Q2 2025 and H1 2025. In millions of euros, unaudited Q2 2024Q2 2025Change H1 2024H1 2025ChangeFarming Supplies 32.833.7+2.7% 62.765.1+3.9%Farming Production 2.93...

 PRESS RELEASE

Croissance de +6,4% du chiffre d’affaires au 1er semestre 2025

Croissance de +6,4% du chiffre d’affaires au 1er semestre 2025 COMMUNIQUE DE PRESSE Loudéac, le 3 septembre 2025 Croissance de +6,4% du chiffre d’affaires au 1er semestre 2025 Toutes les activités du Groupe sont en progression Amélioration de l’EBITDA anticipée sur l’exercice 2025 WINFARM (ISIN : FR0014000P11 – mnémonique : ALWF), 1er groupe français proposant un ensemble de prestations de conseil, de service, et de vente à distance de produits et de solutions au monde agricole et à l’élevage, annonce ce jour la publication du chiffre d’affaires du 2ème trimestre 2025 et en cumul sur ...

 PRESS RELEASE

Pharming Group appoints Kenneth Lynard as Chief Financial Officer

Pharming Group appoints Kenneth Lynard as Chief Financial Officer Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry, recognized for driving financial and operational transformation across complex, multinational organizations. His appointment follows our strong first half 2025 financi...

 PRESS RELEASE

Pharming Group reports second quarter and first half 2025 financial re...

Pharming Group reports second quarter and first half 2025 financial results and provides business update Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribersJoenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptakeSecond q...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch